Drugs.md

Cancer Drugs

Drug	Target Gene	Objective	Reference
5-FU	TYMS - DNA	DNA Replication Inhibitor DNA/RNA Damage	[1]
ABT-888	PARP	DNA Repair Inhibitor	[2]
Sunitinib	RTK Groups	Cell Growth Blocker	[3]
Sorafenib	RTK Groups	Cell Growth Blocker	[4]
Erlotinib	EGFR	Proliferation Inhibitor Apoptosis Activator	[5]
Oxaliplatin	DNA	DNA Damage	[6]
Vinblastine	Tubulin Groups	Cell Division Inhibitor	[7]
AZD1775	Wee1	Apoptosis Activator (Mitosis Activator with Damaged DNA)	[8]
L-778123	FNTA	Cell Proliferation (RAS) Inhibitor	[9]
BEZ-235	PI3K - mTOR	Cell Growth Blocker Metabolism Blocker	[10]
Dinaciclib	CDK	Cell Cycle Blocker	[11]
Geldanamycin	HSP90	Onco-protein Stabilization Inhibitor	[12]
MK-2206	AKT	Down-regulation of Cell Growth and Proliferation	[13]
MK-4827	PARP	DNA Repair Inhibitor	[14]
MK-5108	AURKA	Mitosis Inhibitor	[15]
MK-8669	mTOR	Cell Growth Blocker Metabolism Blocker	[16]
MK-8776	CHEK1	DNA Damage Accumulation Cell Cycle Breaker	[17]
MRK-003	γ-Secretase	Proliferation Inhibitor Apoptosis Activator (Notch Suppressor)	[18]
PD-0325901	MEK1 - MEK2	Proliferation Inhibitor Apoptosis Activator	[19]
Bortezomib	26S Proteasome	Cell Cycle Breaker Apoptosis Activator	[20]
Dasatinib	Abl/Src Kinase	Cell Growth Blocker	[21]
Lapatinib	EGFR-HER2	Cell Growth Blocker	[22]
Temozolomide	DNA	DNA Damage	[23]
Zolinza	HDAC Groups	Cell Growth Inhibitor Apoptosis Activator	[24]
Carboplatin	DNA	DNA Damage	[25]
Cyclophosphamide	DNA	DNA Damage	[26]
Dexamethasone	NR3C1	Immunomodulator	[27]
Doxorubicin	TOP2A - TOP2B	Double Strand Break Accumulation	[28]
Etoposide	TOP2A	Double Strand Break Accumulation	[29]
Gemcitabine	RRM1	DNA Synthesis Inhibitor	[30]
Metformin	AMPK	Proliferation Inhibitor Apoptosis Activator	[31]
Vinorelbine	Tubulin Groups	Cell Division Inhibitor	[32]
Methotrexate	DHFR	Nucleotide Synthesis Inhibitor	[33]
Paclitaxel	Tubulin Groups	Cell Division Inhibitor	[34]
Topotecan	TOP1	DNA Strand Break Accumulation	[35]
SN-38	TOP1	DNA Strand Break Accumulation	[36]

References:

These references are the research studies carried out on these cancer drugs and their targeted gene products. They are not drugs' original publications.

• [1]: 5-fluorouracil: mechanisms of action and clinical strategies.
• [2]: ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
• [3]: Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
• [4]: Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
• [5]: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
• [6]: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.
• [7]: Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
• [8]: Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
• [9]: Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123.
• [10]: PI3K inhibitors in cancer: clinical implications and adverse effects.
• [11]: CDK inhibitors in cancer therapy, an overview of recent development.
• [12]: Role of HSP90 in Cancer.
• [13]: Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use.
• [14]: MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.
• [15]: Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.
• [16]: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regi- mens.
• [17]: ATR/CHK1 inhibitors and cancer therapy.
• [18]: The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
• [19]: A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non–small cell lung cancer.
• [20]: Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
• [21]: Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
• [22]: Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
• [23]: Current and future developments in the use of temozolomide for the treatment of brain tumours.
• [24]: Phase II trial of the histone deacetylase inhibitor vorinostat (ZolinzaTM, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
• [25]: Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.
• [26]: Cyclophosphamide and can- cer: golden anniversary.
• [27]: Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo- immunotherapy strategies.
• [28]: Targeting DNA topoisomerase II in cancer chemotherapy.
• [29]: Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.
• [30]: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
• [31]: Metformin: activation of 5 AMP-activated protein kinase and its emerging potential beyond anti- hyperglycemic action.
• [32]: Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
• [33]: Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiation.
• [34]: Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
• [35]: Inhibition of topoisomerase (DNA) I (TOP1): DNA dam- age repair and anticancer therapy.
• [36]: Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.